506 related articles for article (PubMed ID: 34461078)
1. Circulating maternal placental growth factor responses to low-molecular-weight heparin in pregnant patients at risk of placental dysfunction.
McLaughlin K; Hobson SR; Chandran AR; Agrawal S; Windrim RC; Parks WT; Bowman AW; Sovio U; Smith GC; Kingdom JC
Am J Obstet Gynecol; 2022 Feb; 226(2S):S1145-S1156.e1. PubMed ID: 34461078
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic utility of serial circulating placental growth factor levels and uterine artery Doppler waveforms in diagnosing underlying placental diseases in pregnancies at high risk of placental dysfunction.
Agrawal S; Parks WT; Zeng HD; Ravichandran A; Ashwal E; Windrim RC; Hobson SR; Melamed N; Kingdom JC
Am J Obstet Gynecol; 2022 Oct; 227(4):618.e1-618.e16. PubMed ID: 35644246
[TBL] [Abstract][Full Text] [Related]
3. Low-molecular-weight heparin for prevention of preeclampsia and other placenta-mediated complications: a systematic review and meta-analysis.
Cruz-Lemini M; Vázquez JC; Ullmo J; Llurba E
Am J Obstet Gynecol; 2022 Feb; 226(2S):S1126-S1144.e17. PubMed ID: 34301348
[TBL] [Abstract][Full Text] [Related]
4. Pregnancy outcomes in nulliparous women with positive first-trimester preterm preeclampsia screening test: the Great Obstetrical Syndromes cohort study.
Boutin A; Guerby P; Gasse C; Tapp S; Bujold E
Am J Obstet Gynecol; 2021 Feb; 224(2):204.e1-204.e7. PubMed ID: 32777265
[TBL] [Abstract][Full Text] [Related]
5. Urinary Placental Growth Factor for Prediction of Placental Adverse Outcomes in High-Risk Pregnancies.
Lecarpentier E; Gris JC; Cochery-Nouvellon E; Mercier E; Abbas H; Thadhani R; Karumanchi SA; Haddad B
Obstet Gynecol; 2019 Dec; 134(6):1326-1332. PubMed ID: 31764746
[TBL] [Abstract][Full Text] [Related]
6. Maternal serum levels of soluble fms-like tyrosine kinase-1 and placental growth factor at 20 and 28 weeks of gestational age and the risk of spontaneous preterm birth.
Sovio U; Gaccioli F; Cook E; Charnock-Jones DS; Smith GCS
Am J Obstet Gynecol; 2023 Aug; 229(2):164.e1-164.e18. PubMed ID: 36758709
[TBL] [Abstract][Full Text] [Related]
7. Prediction and prevention of small-for-gestational-age neonates: evidence from SPREE and ASPRE.
Tan MY; Poon LC; Rolnik DL; Syngelaki A; de Paco Matallana C; Akolekar R; Cicero S; Janga D; Singh M; Molina FS; Persico N; Jani JC; Plasencia W; Greco E; Papaioannou G; Wright D; Nicolaides KH
Ultrasound Obstet Gynecol; 2018 Jul; 52(1):52-59. PubMed ID: 29704277
[TBL] [Abstract][Full Text] [Related]
8. High early pregnancy body mass index is associated with alterations in first- and second-trimester angiogenic biomarkers.
Beck C; Allshouse A; Silver RM; Grobman WA; Simhan H; Haas D; Reddy UM; Blue NR
Am J Obstet Gynecol MFM; 2022 May; 4(3):100614. PubMed ID: 35283347
[TBL] [Abstract][Full Text] [Related]
9. The role of aspirin, heparin, and other interventions in the prevention and treatment of fetal growth restriction.
Groom KM; David AL
Am J Obstet Gynecol; 2018 Feb; 218(2S):S829-S840. PubMed ID: 29229321
[TBL] [Abstract][Full Text] [Related]
10. ASPRE trial: risk factors for development of preterm pre-eclampsia despite aspirin prophylaxis.
Shen L; Martinez-Portilla RJ; Rolnik DL; Poon LC
Ultrasound Obstet Gynecol; 2021 Oct; 58(4):546-552. PubMed ID: 33998099
[TBL] [Abstract][Full Text] [Related]
11. Screening for pre-eclampsia at 11-13 weeks' gestation: use of pregnancy-associated plasma protein-A, placental growth factor or both.
Mazer Zumaeta A; Wright A; Syngelaki A; Maritsa VA; Da Silva AB; Nicolaides KH
Ultrasound Obstet Gynecol; 2020 Sep; 56(3):400-407. PubMed ID: 32441401
[TBL] [Abstract][Full Text] [Related]
12. Angiogenic Factor Profiles in Pregnant Women With a History of Early-Onset Severe Preeclampsia Receiving Low-Molecular-Weight Heparin Prophylaxis.
Lecarpentier E; Gris JC; Cochery-Nouvellon E; Mercier E; Touboul C; Thadhani R; Karumanchi SA; Haddad B
Obstet Gynecol; 2018 Jan; 131(1):63-69. PubMed ID: 29215518
[TBL] [Abstract][Full Text] [Related]
13. Placental growth factor predicts time to delivery in women with signs or symptoms of early preterm preeclampsia: a prospective multicenter study.
Barton JR; Woelkers DA; Newman RB; Combs CA; How HY; Boggess KA; Martin JN; Kupfer K; Sibai BM;
Am J Obstet Gynecol; 2020 Mar; 222(3):259.e1-259.e11. PubMed ID: 31518550
[TBL] [Abstract][Full Text] [Related]
14. Comparison of circulating maternal placenta growth factor levels and sonographic evaluation of patients with abnormal first trimester screening analytes.
Ashwal E; Keunen J; Ravichandran A; Ellul K; Agrawal S; Hobson SR; Windrim RC; Kingdom JC
Prenat Diagn; 2023 Jul; 43(8):1044-1055. PubMed ID: 36738445
[TBL] [Abstract][Full Text] [Related]
15. Enoxaparin for the prevention of preeclampsia and intrauterine growth restriction in women with a history: a randomized trial.
Groom KM; McCowan LM; Mackay LK; Lee AC; Said JM; Kane SC; Walker SP; van Mens TE; Hannan NJ; Tong S; Chamley LW; Stone PR; McLintock C;
Am J Obstet Gynecol; 2017 Mar; 216(3):296.e1-296.e14. PubMed ID: 28153659
[TBL] [Abstract][Full Text] [Related]
16. First-trimester screening for early and late preeclampsia using maternal characteristics, biomarkers, and estimated placental volume.
Sonek J; Krantz D; Carmichael J; Downing C; Jessup K; Haidar Z; Ho S; Hallahan T; Kliman HJ; McKenna D
Am J Obstet Gynecol; 2018 Jan; 218(1):126.e1-126.e13. PubMed ID: 29097177
[TBL] [Abstract][Full Text] [Related]
17. Second Trimester Placental Growth Factor Levels and Placental Histopathology in Low-Risk Nulliparous Pregnancies.
Audette MC; McLaughlin K; Kingdom JC
J Obstet Gynaecol Can; 2021 Oct; 43(10):1145-1152.e1. PubMed ID: 33621677
[TBL] [Abstract][Full Text] [Related]
18. Using ultrasound and angiogenic markers from a 19- to 23-week assessment to inform the subsequent diagnosis of preeclampsia.
Lai J; Syngelaki A; Nicolaides KH; von Dadelszen P; Magee LA
Am J Obstet Gynecol; 2022 Aug; 227(2):294.e1-294.e11. PubMed ID: 35276067
[TBL] [Abstract][Full Text] [Related]
19. The prediction of fetal death with a simple maternal blood test at 20-24 weeks: a role for angiogenic index-1 (PlGF/sVEGFR-1 ratio).
Chaiworapongsa T; Romero R; Erez O; Tarca AL; Conde-Agudelo A; Chaemsaithong P; Kim CJ; Kim YM; Kim JS; Yoon BH; Hassan SS; Yeo L; Korzeniewski SJ
Am J Obstet Gynecol; 2017 Dec; 217(6):682.e1-682.e13. PubMed ID: 29037482
[TBL] [Abstract][Full Text] [Related]
20. Pravastatin is useful for prevention of recurrent severe placenta-mediated complications - a pilot study.
Kupferminc MJ; Kliger C; Rimon E; Asher-Landsberg J; Skornick-Rapaport A; Gamzu R; Yogev Y
J Matern Fetal Neonatal Med; 2022 Dec; 35(25):8055-8061. PubMed ID: 34154497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
